Page 124 - 2022_02-Haematologica-web

T. Pincez et al.
Acknowledgments
The list of collaborators is given in the Online Supplementary Appendix. The authors would like to thank all of the patients, families, medical and para-medical teams involved in the CERE- VANCE prospective cohort study from 2004 onwards.
Funding
This work was supported from 2004 by the French Ministry of Health (Programme Hospitalier de Recherche Clinique [PHRC] 2005, Rare Disease Plan 2007 and 2017), the Association
Bordelaise pour l’Avancement des Sciences Pédiatriques (ABASP) research charity, the Association pour la Recherche et les Maladies Hématologiques de l’Enfant (RMHE) research charity, the Association Française du Syndrome d’Evans (AFSE), the O-CYTO patients’ association, and partially by GlaxoSmithKline, AMGEN and Novartis. TP is a recipient of a Charles Bruneau fellowship award.
Data sharing statement
Data are available on request to corresponding author.
References
1.Aladjidi N, Fernandes H, Leblanc T, et al. Evans syndrome in children: long-term out- come in a prospective French national observational cohort. Front Pediatr. 2015;3:79.
2. Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951;87(1):48-65.
3. Mathew P, Chen G, Wang W. Evans syn- drome: results of a national survey. J Pediatr. Hematol Oncol. 1997;19(5):433- 437.
4. Pui CH, Wilimas J, Wang W. Evans syn- drome in childhood. J. Pediatr. 1980;97(5):754–758.
5. Savaşan S, Warrier I, Ravindranath Y. The spectrum of Evans’ syndrome. Arch Dis Child. 1997;77(3):245-248.
6. Wang WC. Evans syndrome in childhood: pathophysiology, clinical course, and treat- ment. Am J Pediatr Hematol Oncol. 1988;10(4):330-338.
7. Blouin P, Auvrignon A, Pagnier A, et al. Syndrome d’Evans : étude rétrospective de la société d’hématologie et d’immunologie pédiatrique (36 cas). Arch Pédiatrie. 2005;12(11):1600-1607.
8. Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national obser- vational study of 265 children. Haematologica. 2011;96(5):655-663.
9. Mannering N, Hansen DL, Frederiksen H. Evans syndrome in children below 13 years of age – a nationwide population-based cohort study. PoS One. 2020; 15(4):e0231284.
10. Pincez T, Neven B, Le Pointe HD, et al. Neurological involvement in childhood Evans syndrome. J Clin Immunol. 2019; 39(2):171-181.
11. Costallat GL, Appenzeller S, Costallat LTL. Evans syndrome and systemic lupus ery- thematosus: clinical presentation and out- come. Joint Bone Spine. 2012;79(4):362- 364.
12. Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell pheno- type and apoptotic response reveal autoim- mune lymphoproliferative syndrome
(ALPS). Blood. 2005;105(6):2443-2448. 13.Hadjadj J, Aladjidi N, Fernandes H, et al. Pediatric Evans syndrome is associated with a high frequency of potentially dam- aging variants in immune genes. Blood.
2019;134(1):9-21.
14. White PH, Cooley WC, Group TCRA, et al.
Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2018;142(5):e20182587.
15. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombo- cytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
16. Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.
17. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classifica- tion for the autoimmune lymphoprolifera- tive syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35-40.
18. Ducassou S, Gourdonneau A, Fernandes H, et al. Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpu- ra: the French experience over the past 25 years. Br J Haematol. 2020;189(5):931-942.
19.Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syn- dromes: genetic defects of apoptosis path- ways. Cell Death Differ. 2003;10(1):124- 133.
20.Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregula- tion syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410- 1416.
21. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014;46(8):812-814.
22.Besnard C, Levy E, Aladjidi N, et al. Pediatric-onset Evans syndrome: heteroge- neous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clin Immunol. 2018;188:52-57.
23. Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient individuals. J. Allergy Clin Immunol. 2018;142(6):1932- 1946.
24. Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoim- mune lymphoproliferative syndrome relat- ed to TNFRSF6 mutation. Blood. 2011; 118(18):4798-4807.
25. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): common variable immunodefi- ciency disorders. J. Allergy Clin Immunol Pract. 2016;4(1):38-59.
26. Tarvin SE, O’Neil KM. Systemic lupus ery- thematosus, Sjögren syndrome, and mixed connective tissue disease in children and adolescents. Pediatr Clin North Am. 2018; 65(4):711-737.
27.Lube GE, Ferriani MPL, Campos LMA, et al. Evans syndrome at childhood-onset sys- temic lupus erythematosus diagnosis: a large multicenter study. Pediatr Blood Cancer. 2016;63(7):1238-1243.
28. Miano M. How I manage Evans Syndrome and AIHA cases in children. Br J Haematol. 2016;172(4):524-534.
29. Lee S, Moon JS, Lee C-R, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J. Allergy Clin Immunol. 2016;137(1):327-330.
30. Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abata- cept therapy. Science. 2015;349(6246):436- 440.
31. Klemann C, Esquivel M, Magerus-Chatinet A, et al. Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoprolifer- ative syndrome. Haematologica. 2017;102(2):e52-e56.
32. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009; 114(15):3167-3172.
33. Gabriel P, McManus M, Rogers K, White P. Outcome evidence for structured pediatric to adult health care transition interven- tions: a systematic review. J Pediatr. 2017; 188:263-269.
466
haematologica | 2022; 107(2)